Cold agglutinin disease (CAD) is treated through a combination of cold avoidance, therapies that target the immune cells driving the disease, and newer drugs that block the destruction of red blood cells. With a prevalence of roughly 14 to 33 per million people in the U.S., CAD is rare, and treatment strategies have shifted significantly in recent years as new options have become available. The right approach depends on whether the disease is primary (arising on its own) or secondary to an infection or blood cancer, and on how severe the anemia is.
What Happens in CAD
In CAD, your immune system produces antibodies that react best at cold temperatures, binding to the surface of red blood cells when your body cools even slightly. Once those antibodies latch on, they activate a chain reaction in the complement system, a part of your immune defense that normally fights infections. This complement activation tags your red blood cells for destruction, breaking them apart faster than your body can replace them. The result is hemolytic anemia: fatigue, weakness, dark urine, and sometimes a bluish discoloration of the fingers, toes, ears, or nose (acrocyanosis) when exposed to cold.
One important distinction: steroids, which are a cornerstone treatment for many other autoimmune anemias, do not work in CAD. This catches some patients and even some physicians off guard, because corticosteroids are often tried first when autoimmune hemolytic anemia is suspected. If you have CAD specifically, steroids should not be part of your treatment plan.
Primary Versus Secondary CAD
Primary CAD is a chronic condition driven by a small, abnormal clone of immune B cells in the bone marrow. It tends to affect older adults and requires long-term management. Secondary cold agglutinin syndromes, by contrast, are triggered by an underlying cause. Common infectious triggers include Mycoplasma pneumoniae (a type of bacterial pneumonia), Epstein-Barr virus (the virus behind mononucleosis), cytomegalovirus, hepatitis B and C, and influenza A. On the malignancy side, lymphoplasmacytic lymphoma, marginal zone lymphoma, and Waldenström macroglobulinemia can all drive cold agglutinin production.
When the cause is an infection, the cold agglutinin problem often resolves once the infection clears. Treatment focuses on the underlying infection, with supportive care (transfusions, cold avoidance) in the meantime. When a lymphoma is responsible, treating the cancer typically improves or resolves the hemolysis. Primary CAD, because it has no removable trigger, requires its own targeted therapy.
Cold Avoidance and Everyday Precautions
For every CAD patient, regardless of disease severity, avoiding cold exposure is the foundation of management. The antibodies that drive red blood cell destruction bind most actively at temperatures between 0 and 4°C (32–39°F), but they can cause problems at warmer temperatures too, especially if the antibodies have a high “thermal amplitude,” meaning they remain active closer to body temperature.
In practical terms, this means dressing warmly, covering your hands, ears, and face in cool weather, and keeping your home at a comfortable temperature. Some patients need to avoid cold food and beverages and should wear gloves when reaching into the refrigerator or freezer. During medical visits or hospital stays, all intravenous fluids and blood products should be warmed before infusion. Without warming, transfused blood can trigger a surge of hemolysis severe enough to block the IV line entirely.
Complement Inhibition With Sutimlimab
Sutimlimab (brand name Enjaymo) was the first drug approved specifically for CAD. Rather than going after the B cells producing the problematic antibodies, it blocks the complement cascade, the immune chain reaction that actually destroys red blood cells. This means it can rapidly reduce hemolysis and raise hemoglobin levels, often within the first week or two of treatment.
The drug is given as an intravenous infusion. Patients weighing under 75 kg receive 6,500 mg per dose; those at 75 kg or above receive 7,500 mg. The schedule starts with weekly infusions for the first two weeks, then shifts to every two weeks. In the pivotal trial, 71% of patients achieved transfusion independence from week 5 through week 26, a meaningful improvement for people who had been relying on regular blood transfusions.
Because sutimlimab doesn’t eliminate the B-cell clone producing the cold agglutinins, it manages symptoms rather than curing the disease. If you stop the infusions, hemolysis typically returns. The ongoing infusion schedule is a significant commitment, but for patients with severe, transfusion-dependent anemia, the improvement in quality of life can be substantial.
B-Cell Directed Therapy
The other main treatment strategy targets the root cause: the abnormal B cells churning out cold agglutinins. Rituximab, an antibody that depletes B cells, is the most established option. Used alone, rituximab produces a response in roughly 45 to 60% of patients. Responses tend to take several weeks to develop, since the drug needs time to clear out the offending cells.
Combining rituximab with a chemotherapy drug improves results. Rituximab plus fludarabine achieves an overall response rate of about 76%, though this combination carries more side effects. Rituximab plus bendamustine is another option, particularly for patients who haven’t responded to other regimens. In case reports, bendamustine-based combinations have produced complete responses lasting over three years.
B-cell directed therapy has the advantage of potentially inducing a durable remission, meaning you may not need continuous treatment. The trade-off is that these are more intensive regimens with real side effects, including increased infection risk while the immune system is suppressed. The choice between complement inhibition and B-cell therapy often comes down to how urgently the anemia needs to be controlled, your overall health, and whether a long-term remission is a realistic goal.
Managing Acute Crises
CAD can flare dramatically during cold weather, infections, or surgery. When hemoglobin drops dangerously low and symptoms become severe, the situation requires urgent intervention. Blood transfusions are given through an in-line blood warmer to prevent the transfused cells from triggering even more hemolysis.
Plasmapheresis, a procedure that filters the blood to remove the IgM antibodies driving the destruction, can provide rapid but temporary relief. A single exchange of 1 to 1.5 times the plasma volume can significantly reduce antibody levels and improve anemia. In adults, plasmapheresis is a bridge: it buys time while longer-acting therapies are started. In children, who more often have infection-triggered cold agglutinin problems, plasmapheresis may be all that’s needed while the underlying infection resolves on its own.
Newer Approaches on the Horizon
Several newer therapies are in development. Bruton’s tyrosine kinase (BTK) inhibitors, already used in certain blood cancers, are being studied for their ability to shut down the B-cell signaling that drives cold agglutinin production. Plasma cell-directed therapies aim at the cells that actually secrete the antibodies. Novel complement inhibitors are also being developed, including an oral small molecule inhibitor of the classical complement pathway (ANX1502) currently in a proof-of-concept study for CAD, with results expected in 2026. An oral option would be a significant shift for patients currently managing their disease through regular IV infusions.
Choosing a Treatment Strategy
Not every CAD patient needs drug therapy. If your anemia is mild and your symptoms are manageable with cold avoidance alone, watchful monitoring may be appropriate. Treatment is typically considered when hemoglobin drops low enough to cause fatigue, exercise intolerance, or shortness of breath, or when you’re becoming dependent on transfusions.
For patients who do need treatment, the decision between complement inhibition and B-cell therapy depends on several factors. Sutimlimab works fast and is well tolerated, making it a strong choice when rapid improvement matters or when chemotherapy-based regimens are too risky. B-cell directed therapy takes longer to show results but offers the possibility of months or years without any treatment. Some patients may use both approaches at different points in their disease course: complement inhibition for immediate control, followed by B-cell therapy aimed at a longer remission.